Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

被引:1420
作者
Spranger, Stefani [1 ]
Spaapen, Robbert M. [1 ]
Zha, Yuanyuan [2 ]
Williams, Jason [1 ]
Meng, Yuru [1 ]
Ha, Thanh T. [1 ]
Gajewski, Thomas F. [1 ,2 ]
机构
[1] Univ Chicago, Dept Pathol, Hematol Oncol Sect, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
关键词
CLINICAL ACTIVITY; HOMEOSTATIC PROLIFERATION; ANTITUMOR IMMUNITY; DENDRITIC CELLS; GENE SIGNATURE; REJECTION; RESPONSES; EXPRESSION; SAFETY; COSTIMULATION;
D O I
10.1126/scitranslmed.3006504
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Tumor escape from immune-mediated destruction has been associated with immunosuppressive mechanisms that inhibit T cell activation. Although evidence for an active immune response, including infiltration with CD8(+) T cells, can be found in a subset of patients, those tumors are nonetheless not immunologically rejected. In the current report, we show that it is the subset of T cell-inflamed tumors that showed high expression of three defined immunosuppressive mechanisms: indoleamine-2,3-dioxygenase (IDO), PD-L1/B7-H1, and FoxP3(+) regulatory T cells (T-regs), suggesting that these inhibitory pathways might serve as negative feedback mechanisms that followed, rather than preceded, CD8(+) T cell infiltration. Mechanistic studies in mice revealed that up-regulated expression of IDO and PD-L1, as well as recruitment of Tregs, in the tumor microenvironment depended on the presence of CD8(+) T cells. The former was driven by interferon-gamma and the latter by a production of CCR4-binding chemokines along with a component of induced proliferation. Our results argue that these major immunosuppressive pathways are intrinsically driven by the immune system rather than being orchestrated by cancer cells, and imply that cancer immunotherapy approaches targeting negative regulatory immune checkpoints might be preferentially beneficial for patients with a preexisting T cell-inflamed tumor microenvironment.
引用
收藏
页数:10
相关论文
共 49 条
[1]   New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site [J].
Appay, Victor ;
Jandus, Camilla ;
Voelter, Verena ;
Reynard, Severine ;
Coupland, Sarah E. ;
Rimoldi, Donata ;
Lienard, Danielle ;
Guillaume, Philippe ;
Krieg, Arthur M. ;
Cerottini, Jean-Charles ;
Romero, Pedro ;
Leyvraz, Serge ;
Rufer, Nathalie ;
Speiser, Daniel E. .
JOURNAL OF IMMUNOLOGY, 2006, 177 (03) :1670-1678
[2]  
Atkins MB, 2000, CANCER J SCI AM, V6, pS11
[3]   ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo [J].
Blank, C ;
Brown, I ;
Kacha, AK ;
Markiewicz, MA ;
Gajewski, TF .
JOURNAL OF IMMUNOLOGY, 2005, 174 (06) :3416-3420
[4]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[5]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[6]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[7]   Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection [J].
Brown, Ian E. ;
Blank, Christian ;
Kline, Justin ;
Kacha, Aalok K. ;
Gajewski, Thomas F. .
JOURNAL OF IMMUNOLOGY, 2006, 177 (07) :4521-4529
[8]   COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4 [J].
CHEN, LP ;
ASHE, S ;
BRADY, WA ;
HELLSTROM, I ;
HELLSTROM, KE ;
LEDBETTER, JA ;
MCGOWAN, P ;
LINSLEY, PS .
CELL, 1992, 71 (07) :1093-1102
[9]   Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation [J].
Chen, SH ;
Pham-Nguyen, KB ;
Martinet, O ;
Huang, YZ ;
Yang, W ;
Thung, SN ;
Chen, LP ;
Mittler, R ;
Woo, SLC .
MOLECULAR THERAPY, 2000, 2 (01) :39-46
[10]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949